| | | | |
CUSIP No. 77634L 105 | | Schedule 13D | | Page 11 of 14 |
This Amendment No. 6 (the “Amendment”) amends and supplements the Schedule 13D filed by the Reporting Persons on July 1, 2022, as amended on October 3, 2023, February 7, 2024, February 26, 2024, April 29, 2024 and May 7, 2024 (collectively, the “Original Schedule 13D” and, as amended and supplemented by this Amendment, this “Statement”), with respect to the Common Stock. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.
Item 4. Purpose of Transaction.
Item 4 of the Original Schedule 13D is amended and supplemented by adding the following:
On June 12, 2024, the Investor Parties submitted a request to the Issuer to extend the deadline under the May 6 Waiver in order to permit the Investor Parties to continue discussions with respect to a Potential Transaction through July 12, 2024 (the “June 12 Waiver Request”), and such request has been granted.
The foregoing description of the June 12 Waiver Request is not intended to be complete and is qualified in its entirety by reference to the full text of the June 12 Waiver Request. The June 12 Waiver Request is filed as Exhibit 7 hereto.
As permitted by the May 6 Waiver, the Reporting Persons have been engaged in discussions with TCP-ASC with respect to a Potential Transaction throughout the past several weeks. In connection with these discussions, Jeremy Delinsky, a NMC Designee on the Board (“Mr. Delinsky”), has and intends to continue to assist the Reporting Persons in conducting due diligence on the Issuer. The Reporting Persons and Mr. Delinsky have had preliminary discussions and intend to continue to have discussions regarding the possibility of Mr. Delinsky serving in an executive capacity and/or advisory role with the Issuer following such Potential Transaction.
The Reporting Persons and their affiliates are engaged in ongoing discussions and negotiations with TCP-ASC, Mr. Delinsky and other existing stockholders and potential financing sources. The Reporting Persons and their affiliates have not reached any agreement, arrangement or understanding with any other person (including TCP-ASC or Mr. Delinsky) regarding any Potential Transaction. The Reporting Persons disclaim membership in any “group” (within the meaning of Section 13(d)(3) of the Act) with TCP-ASC or Mr. Delinsky and also expressly disclaim the beneficial ownership of any shares of Common Stock held by either TCP-ASC or Mr. Delinsky. There is no assurance that any such discussions will continue or that any such group may be formed.
TowerBrook Capital Partners L.P., Ascension Health Alliance d/b/a Ascension, and New Mountain Capital, L.L.C. have come to an understanding with respect to the sharing of certain expenses incurred in connection with the evaluation, negotiation, pursuit or consummation of a Potential Acquisition.
Item 5. Interest in Securities of the Issuer.
Item 5 of the Original Schedule 13D is amended and restated in its entirety as follows:
The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Statement and the information set forth or incorporated in Items 2, 3, 4 and 6 is incorporated by reference in its entirety into this Item 5.
(a) and (b) The percentages in this Item 5 and in other provisions of this Statement relating to beneficial ownership of Common Stock are based on based on 421,255,230 shares of Common Stock outstanding as of May 8, 2024, as reported by the Issuer in the Form 10-Q.
(c) None of the Reporting Persons has effected any transaction in the shares of Common Stock during the past 60 days.
(d) No other person is known to the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this Statement.
(e) Not applicable.